• Expansion marks progress in the development of wearable biosensing platform to monitor multiple key biomarkers in real-time
• Study expected to demonstrate the capability of Rockley’s Bioptx™ biosensing band to monitor and measure multiple biomarkers, including core body temperature and hydration, more accurately than other commonly available tools and wrist-worn devices

Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”), a global leader in photonics-based health monitoring and communications solutions, today announced the expansion of its free-living human study to a broader population of participants. The study will test the capability of its Bioptx™ biosensing band to remotely monitor and measure key biomarkers including core body temperature and hydration outside a laboratory setting.

Rockley’s biosensing technology is expected to advance health and wellness tracking by enabling wearable monitoring devices to capture critical data of multiple biomarkers more accurately and in real-time. The study expansion is based on strong initial free-living human study results that showed Rockley’s technology provided accurate biomarker measurements. The study is expected to capture data from 50 subjects and should be completed in the fourth quarter of 2022.

Results from Rockley’s study are expected to confirm the accuracy of Rockley’s biosensing technology platform. Potential important applications for health and wellness include continuous monitoring of the circadian rhythm, fever detection, fertility cycle, and sleep patterns.

Accurate measurement of biomarkers such as core body temperature and hydration are critical in monitoring and tracking basic health and wellness. Existing wearable devices simply measure skin temperature, leading to imprecise indications of temperature. And without a “gold standard” of measurement, determining the hydration level of a patient is costly and time-consuming. By enabling the accurate detection of biomarkers from a wearable monitoring device and tracking them over time, Rockley’s biosensing platform has the potential to provide real-time insights about a variety of health conditions and to provide early indications of changes to an individual’s health.

Dr. Andrew Rickman, chairman and chief executive officer of Rockley, said: “The expansion of Rockley’s free-living study using our Bioptx biosensing band brings us closer to advancing healthcare and wellness monitoring to the next level. Many important biomarkers like core body temperature are not accurately or conveniently monitored using existing tools and even the latest wrist-worn devices, yet they are core vital signs, providing critical clues to human health. In my own free-living experience while testing the Bioptx biosensing band over several months, the solution correctly detected a fever the day before I was impacted by an illness. I believe that our solution will provide people with information that will help them live healthier lives and this free-living study will help us demonstrate the power of our device.”

More information about Rockley’s digital health monitoring solution is available here: https://rockleyphotonics.com/healthcare-sensing

About Rockley Photonics

A global leader in photonics-based health monitoring and communications solutions, Rockley Photonics is developing a comprehensive range of photonic integrated circuits and associated modules, sensors, and full-stack solutions. From next-generation sensing platforms specifically designed for mobile health monitoring and machine vision to high-speed, high-volume solutions for data communications, Rockley is laying the foundation for a new generation of applications across multiple industries. Rockley believes that photonics will eventually become as pervasive as micro-electronics, and it has developed a platform with the power and flexibility needed to address both mass markets and a wide variety of vertical applications.

Formed in 2013, Rockley is uniquely positioned to support hyper-scale manufacturing and address a multitude of high-volume markets. Rockley has partnered with numerous tier-1 customers across a diverse range of industries to deliver the complex optical systems required to bring transformational products to market.

To learn more about Rockley, visit rockleyphotonics.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release that are not historical facts constitute “forward-looking statements” for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding Rockley’s future expectations, beliefs, plans, objectives, and assumptions regarding future events or performance. The words “accelerate,” “advance,” “anticipate,” “believe,” “can,” “capability,” “continue,” “could,” “develop,” “enable,” “estimate,” “eventual,” “expand, “expect,” “focus,” “forward,” “future,” “goal,” “intend,” “may,” “might,” “opportunity,” “outlook,” “plan,” “possible,” “position,” “potential,” “predict,” “project,” “revolutionize,” “seem,” “should,” “trend,” “vision,” “will,” “would” or other terms that predict or indicate future events, trends, or expectations, and similar expressions or the negative of such expressions may identify forward-looking statements, but the absence of these words or terms does not mean that a statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, statements regarding the following: (a) our expectations regarding our expanded free-living study, including expected results and timing; (b) the ability of our biosensing technology platform to monitor changes to human cycles such as the circadian rhythm, fever detection, fertility, and sleep patterns; (c) the ability of our biosensing platform to provide accurate detection of biomarkers from a wearable monitoring device and track them over time; (d) the ability of Rockley’s biosensing platform to provide real-time insights about a variety of health conditions and to provide early indications of changes to an individual’s health; (e) our ability to advance healthcare and wellness monitoring to the next level; (f) our belief that important biomarkers are not accurately or conveniently monitored using existing tools and devices; (g) our belief that we are laying the foundation for a new generation of applications across multiple industries; (h) the anticipated and potential features, scope, goals, and benefits of the Company’s platform, products, and technology; (i) Rockley’s belief that photonics will eventually become as pervasive as micro-electronics; (j) the ability of our platform to address both mass markets and a wide variety of vertical applications; and (k) Rockley’s potential to support hyper-scale manufacturing, address a multitude of high-volume markets, and deliver the complex optical systems required to bring transformational products to market.

Forward-looking statements are subject to several risks, assumptions, and uncertainties (many of which are beyond Rockley’s control) that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, assumptions, and uncertainties include, but are not limited to, the factors described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 and in other documents we file with the Securities and Exchange Commission. If any of these risks or uncertainties materialize, or should any of these assumptions prove incorrect, actual results may differ materially from those discussed in or implied by these forward-looking statements. There can be no assurance that future developments affecting Rockley will be those that have been anticipated. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof and Rockley does not intend to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221006005997/en/